What is BiomX Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BiomX's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.99.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, BiomX couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for BiomX's Cash-to-Debt or its related term are showing as below:
PHGE'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.99 Med: 1.72 Max: 9.56
Current: 0.99
During the past 6 years, BiomX's highest Cash to Debt Ratio was 9.56. The lowest was 0.99. And the median was 1.72.
BiomX Cash-to-Debt Historical Data
The historical data trend for BiomX's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BiomX Cash-to-Debt Chart
|
BiomX Annual Data
|
|
Trend |
Jun18 |
Jun19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
1.39 |
9.56 |
3.10 |
1.72 |
0.99 |
|
BiomX Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
1.72 |
1.56 |
1.69 |
1.39 |
0.99 |
Competitive Comparison of BiomX's Cash-to-Debt
For the Biotechnology subindustry, BiomX's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiomX's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiomX's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where BiomX's Cash-to-Debt falls into.
BiomX Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
BiomX's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
BiomX's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiomX (PHGE) Business Description
Traded in Other Exchanges
N/A
Address
22 Einstein Street, Floor 5, Ness Ziona, ISR, 7414003
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis.
Executives
| Assaf Oron |
officer: Chief Business Officer |
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Eddie Williams |
director |
260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Michael E. Dambach |
director |
22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003 |
| Jason M. Marks |
director |
C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807 |
| Carl L Gordon |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Orbimed Israel Biofund Gp Limited Partnership |
director, 10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
| Chidozie Ugwumba |
10 percent owner |
158 FILMORE STREET, DENVER CO 80206 |
| Thomas Layton Walton |
10 percent owner |
P.O. BOX 1860, BENTONVILLE AR 72712 |
| Paul J Sekhri |
director |
C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
| Lynne Marie Sullivan |
director |
C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139 |
| Marina Wolfson |
officer: Principal Financial Officer |
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Jonathan Eitan Solomon |
director, officer: Chief Executive Officer |
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Alan Charles Moses |
director |
C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Russell Greig |
director |
C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM |
| Gbolahan Amusa |
director |
17 STATE STREET 21 FLOOR, NEW YORK NY 10004 |
BiomX (PHGE) Headlines
Lifshitz & Miller LLP Announces Investigation of Altria Group, Inc., Chardan Healthcare Acquisition Corporation, Premier, Inc., Restoration Robotics, Inc., Vivint Solar, Inc., Waitr Holdings Inc., Xilinx, Inc., and Zscaler, Inc.
By PRNewswire PRNewswire
•
10-10-2019
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PHGE has been successfully added to your